- Home
- HPK vs ALVO Comparison
HPK vs ALVO Comparison
Compare HPK & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HPK | ALVO |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HPK | ALVO |
|---|---|---|
| Price | $8.03 | $5.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $8.00 |
| AVG Volume (30 Days) | 417.0K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $863,359,000.00 | N/A |
| Revenue This Year | N/A | $13.28 |
| Revenue Next Year | N/A | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.85 | $2.94 |
| 52 Week High | $9.13 | $9.25 |
Technical Indicators
Market Signals| Indicator | HPK | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 50.06 | 75.24 |
| Support Level | $7.40 | $3.10 |
| Resistance Level | $8.49 | $5.85 |
| Average True Range (ATR) | 0.46 | 0.25 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 33.45 | 84.33 |
Price Performance
Historical ComparisonAbout HPK HighPeak Energy Inc.
HighPeak Energy Inc is an independent crude oil and natural gas exploration and production company that explores for, develops and produces crude oil, NGL, and natural gas prominently in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S. The majority of the company's revenue is derived from the Crude oil sales.
About ALVO Alvotech
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.